Lastly, Retatrutide, a triple agonist of GCGR/GIPR/GLP1R, showed dose-dependent reductions in liver fat and high rates of NASH resolution phase IIa trial [155]. This evidence concerns the gene GIPR and metabolic dysfunction-associated steatohepatitis.